Last reviewed · How we verify
unlabelled hMAb BIWA 4 - high dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
unlabelled hMAb BIWA 4 - high dose (unlabelled hMAb BIWA 4 - high dose) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| unlabelled hMAb BIWA 4 - high dose TARGET | unlabelled hMAb BIWA 4 - high dose | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- unlabelled hMAb BIWA 4 - high dose CI watch — RSS
- unlabelled hMAb BIWA 4 - high dose CI watch — Atom
- unlabelled hMAb BIWA 4 - high dose CI watch — JSON
- unlabelled hMAb BIWA 4 - high dose alone — RSS
Cite this brief
Drug Landscape (2026). unlabelled hMAb BIWA 4 - high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/unlabelled-hmab-biwa-4-high-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab